Lion Point Capital »

Kura Oncology shares owned by Lion Point Capital

Quarter-by-quarter ownership of Kura Oncology (KURA) shares owned by Lion Point Capital from 13F filings

Historical chart of Lion Point Capital investment in Kura Oncology

Tip: Access up to 7 years of quarterly data

All positions including Kura Oncology held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kura Oncology by Lion Point Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $407k 46k 8.85

More positions owned by Lion Point Capital

Mineralys Therapeutics (MLYS)
Milestone Pharmaceuticals (MIST)
Fennec Pharmaceuticals (FENC)
Jasper Therapeutics Com New (JSPR)
Avadel Pharmaceuticals Com Shs (AVDL)
Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Insmed Com Par $.01 (INSM)
Ardelyx (ARDX)
Benitec Biopharma Com New (BNTC)
Syndax Pharmaceuticals (SNDX)
Royalty Pharma Shs Class A (RPRX)
Disc Medicine (IRON)
Bridgebio Pharma (BBIO)
Geron Corporation (GERN)
Arcutis Biotherapeutics (ARQT)

View all positions for Lion Point Capital

Top funds holding Kura Oncology

BlackRock
BVF
Suvretta Capital Management
Vanguard Group
Armistice Capital
State Street Corporation
Prosight Management
Goldman Sachs Group
AQR Capital Management
Jacobs Levy Equity Management
Millennium Management
Geode Capital Management
Morgan Stanley
Qube Research & Technologies
Alethea Capital Management

View all funds holding Kura Oncology